• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
BiDil: Race Medicine Or Race Marketing?
BiDil: Race Medicine Or Race Marketing?

... parts or that two generics combined differed essentially from the two generics separated, there was no patent to apply for, no NDA forthcoming, thus no money to be made, and so no research conducted. Indeed, Cohn himself bemoaned the lack of relevant intellectual property rights as undermining indus ...
Slide 1
Slide 1

... because the patients weren't taking it and not because the drug didn't work, an analysis of the study results suggests. • A subsequent analysis of urine samples retained from the study showed that fewer than 40 percent of 53 patients in the vigabatrin arm who completed the 12-week study had urine dr ...
drug-Sedatatives
drug-Sedatatives

...  Sold OTC until banned by FDA in 1990.  Became a Schedule I Controlled Substance in 2000.  Produced in clandestine laboratories with inexpensive ingredients using recipes on the internet.  Surpassed Rohypnol as the ‘date rape’ drug.  Has synergistic effect with alcohol.  'Date rape' drug GHB m ...
Strategies in Designing Clinicals for Fixed
Strategies in Designing Clinicals for Fixed

Lehman Brothers 2008 Global Healthcare Conference
Lehman Brothers 2008 Global Healthcare Conference

New ABPI Code of Practice – what difference will the new
New ABPI Code of Practice – what difference will the new

... and impacting on length of stay. ...
Instantaneous Inhibitory Potential and Inhibitory Quotient Show a
Instantaneous Inhibitory Potential and Inhibitory Quotient Show a

... There now are 12 dozen US Food and Drug Administration–, Health Canada–, and European Union–approved antiretroviral agents from 6 distinct classes that are used in combination for the treatment of human immunodeficiency virus (HIV) infection. These drugs have been introduced at the rate of ∼1 per ye ...
Finally, a Balance Between Safety and Effectiveness in
Finally, a Balance Between Safety and Effectiveness in

New drug development and approval process
New drug development and approval process

...  This type of protocol is termed a treatment IND.  Treatment INDs often sought for orphan drugs, which are targeted for small numbers of patients who have rare conditions or diseases for which there are no satisfactory alternative treatments.  For certain changes in a previously approved NDA, suc ...
BLIND A condition imposed on an individual (or group of individuals
BLIND A condition imposed on an individual (or group of individuals

BSc in Medical Sciences with PHARMACOLOGY Course Director Dr
BSc in Medical Sciences with PHARMACOLOGY Course Director Dr

Hetlioz - Health Net
Hetlioz - Health Net

... This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreeme ...
vol.13 No.2 - TU Teaching Hospital
vol.13 No.2 - TU Teaching Hospital

... kinetic characteristics of the drugs. For example, the poorly water soluble antiretroviral drug saquinavir should be taken with food to allow bile enhancement of its dissolution which then facilitates absorption. Delayed gastric emptying after a meal and the associated gastric acid secretions can re ...
CHANTIX (varenicline tartrate )
CHANTIX (varenicline tartrate )

... The drug received a priority review because of its significant potential benefit to public health. Chantix was reviewed in six months rather than the regular review time of 10 months, says Curt Rosebraugh, M.D., M.P.H., deputy director of the FDA's Office of Drug Evaluation II. "Chantix underwent pr ...
ironwood and forest announce linaclotide new drug application for
ironwood and forest announce linaclotide new drug application for

... Forest Laboratories’ (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective and respiratory medicine. ...
About ATODA
About ATODA

... effects of opioid overdose. Naloxone is widely used in Australia and internationally by paramedics and emergency room staff in cases of suspected opioid overdose. It has no psychoactive effect, is not a drug of dependence, and therefore, is not a substance which is likely to be diverted or misused. ...
No Slide Title
No Slide Title

... IS IT SAFE? • Adverse drug reactions (ADRs) represent the 4th leading cause of hospitalization and is responsible for 100,000 deaths/yr in the U.S. 2 million hospitalizations/yr in US ...
Read More… - Envisia Therapeutics
Read More… - Envisia Therapeutics

... Envisia uses the power of the proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology to create particle-based ocular therapeutics that can deliver both small and large molecules in multiple formats. Envisia’s lead product, ENV515, is a marketed prostaglandin analogue that uses ...
Overview of Data Exclusivity and Patent/Registration Linkage
Overview of Data Exclusivity and Patent/Registration Linkage

... Data exclusivity prevents a drug regulatory authority from relying on clinical and other data provided by the first registrant of a medicine, or from relying on the fact of prior product registration in that same country or elsewhere in order to access the safety and efficacy of a therapeutically eq ...
Sensilux -Pil-ang
Sensilux -Pil-ang

... If you suffer from some of the hereabove stated defects, inform your doctor about. Unwanted effects: The product is very well tolerated. However, in case of overapplication (very long time or very often), relative congestion, conjunctiva irritation, pricking, itching and burning in eye may occur. Ra ...
TERATOLOGY - Univerzita Karlova
TERATOLOGY - Univerzita Karlova

... Positive evidence of human fetal risk exists, but benefits in certain situations (eg, life-threatening situations or serious diseases for which safer drugs cannot be used or are ineffective) may make use of the drug acceptable despite its risks. Studies in animals or humans have demonstrated fetal a ...
safety - Moodle Lille 2
safety - Moodle Lille 2

...  Event rates for males observed in the active treatment arms significantly exceeded the rates expected in an age-matched reference diabetic population.  “Dr. Hampp points out that the limitations of these analyses preclude a conclusion of an association between dapagliflozin treatment and bladder ...
Lecture 2
Lecture 2

... (desensitization) • Decreased response to same dose with repeated exposure • or more drug needed to achieve same effect • Right-ward shift of D-R curve • Sometimes occurs in an acute dose (e.g. alcohol) • Can develop across drugs (crosstolerance) • Caused by compensatory mechanisms that oppose the e ...
DOSE *RESPONSE CURVES
DOSE *RESPONSE CURVES

... DOSE –RESPONSE CURVES LAKSHMAN KARALLIEDDE OCTOBER 2011 ...
IDE_IND_KMFINAL_plusAEslide_090310
IDE_IND_KMFINAL_plusAEslide_090310

... for its effects on diseases in the proposed investigation (i.e., to cure, treat, mitigate, prevent, or diagnose disease including its associated symptoms), then it is an investigational new drug and will be subject to IND requirements. This applies to studies in INDs sponsored for both commercial an ...
< 1 ... 147 148 149 150 151 152 153 154 155 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report